Correction: Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Crossref DOI link: https://doi.org/10.1038/srep38270
Published Online: 2016-12-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Xu, Jianlin
Yang, Haitang
Jin, Bo
Lou, Yuqing
Zhang, Yanwei
Zhang, Xueyan
Zhong, Hua
Wang, Huiming
Wu, Dan
Han, Baohui
Text and Data Mining valid from 2016-12-01
Version of Record valid from 2016-12-01
Article History
First Online: 1 December 2016